INTRODUCTION
============

In consonant with a close proximity in anatomy, coordinated development of the circulatory system including vessels, blood and the heart is prerequisite for securing successful embryogenesis. In developing embryos, the growth of the circulatory system is identifiable first and abnormalities in the establishment of the system frequently cause embryonic lethality. As early as embryonic day (E) 7.5 in mice, the first structure with the signature of endothelial and hematopoietic cells is the blood islands of the extraembryonic yolk sac ([@b31-molce-38-12-1029]). Shortly after, the blood islands, which have erythrocytes inside the lumen circled by a layer of endothelial cells, fuse together to create primitive forms of vessels (i.e., primary plexus), which then undergo a remodeling process, generating the complex vascular network interwoven by small capillary vessels and large vessels. On the other hand, angioblasts (also known as endothelial precursor cells) initiate the formation of the vascular structures in the embryonic proper such as dorsal aorta, cardinal veins, vitelline vessels ([@b21-molce-38-12-1029]; [@b27-molce-38-12-1029]; [@b72-molce-38-12-1029]). The more elaborated vasculatures are further completed through vascular reshaping, recruitment of perivascular cells and deposition of the extracellular matrix ([@b11-molce-38-12-1029]; [@b42-molce-38-12-1029]). While the blood cells that first appear in the yolk sacs are mainly erythrocytes and macrophages in the blood islands ([@b12-molce-38-12-1029]; [@b68-molce-38-12-1029]), hematopoietic stem cells, which can supply all types of blood cells throughout the adult life, are detected in the specialized region of the dorsal aorta ([@b6-molce-38-12-1029]; [@b7-molce-38-12-1029]; [@b47-molce-38-12-1029]; [@b109-molce-38-12-1029]) and sequentially populate the fetal liver, spleen and bone marrow.

Transcriptional factors have been implicated in a myriad of biological processes including embryogenesis, tumor and cell proliferation. Among are the E26 transforming sequence or E-twenty-six specific sequence (ETS) transcription factors, which are categorized by the presence of the ETS DNA binding domain ([Fig. 1A](#f1-molce-38-12-1029){ref-type="fig"}) ([@b37-molce-38-12-1029]). Extensive studies have revealed important functions of the ETS factors in endothelial and hematopoietic cell development ([@b2-molce-38-12-1029]; [@b14-molce-38-12-1029]; [@b20-molce-38-12-1029]; [@b26-molce-38-12-1029]; [@b74-molce-38-12-1029]). For example, compound knockouts of *Ets1* and *Ets2* show abnormal endothelial cell branching ([@b103-molce-38-12-1029]). While *Fli1* null mouse embryos develop vascular leakage due to enhanced endothelial cell death ([@b33-molce-38-12-1029]; [@b85-molce-38-12-1029]), the lack of *Tel1* in mice leads to defective vascular remodeling in the yolk sac and is accompanied by considerable apoptosis ([@b102-molce-38-12-1029]). However, emergence of the vascular structures is not blocked by the absence of these ETS factors and the inactivation of *Ets1* does not cause vascular defects ([@b3-molce-38-12-1029]). This fact suggests the redundant functions of the ETS factors for at least some members in vessel development ([@b16-molce-38-12-1029]; [@b73-molce-38-12-1029]; [@b103-molce-38-12-1029]). In contrast, recent studies have discovered the non-redundant and indispensable role of one of the ETS factors, ETV2 in vessel as well as blood cell development ([@b25-molce-38-12-1029]; [@b44-molce-38-12-1029]; [@b52-molce-38-12-1029]). In this review, we will discuss the functional significance of ETV2 in embryonic vessel development, postnatal angiogenesis and direct cell reprogramming.

ETV2 IS ESSENTIAL FOR VASCULAR ENDOTHELIAL AND HEMATOPOIETIC CELL DEVELOPMENT
=============================================================================

ETV2 has drawn a great deal of attention as an important regulator for embryonic vessel and blood cell development. Structurally, ETV2 shares a conserved ETS DNA binding domain with other ETS factors but does not exhibit any similarities outside this domain ([@b9-molce-38-12-1029]; [@b17-molce-38-12-1029]; [@b18-molce-38-12-1029]). Although identified as a testis specific protein in adults ([@b9-molce-38-12-1029]; [@b18-molce-38-12-1029]), accumulative data show that ETV2 is expressed in early mouse embryos. Its expression is first recognizable in mesodermal progenitors, which can generate cardiovascular lineages between E7.0 and E7.5 ([@b25-molce-38-12-1029]; [@b44-molce-38-12-1029]; [@b52-molce-38-12-1029]; [@b75-molce-38-12-1029]). At later stages, *Etv2* is detected in specific vasculatures including the dorsal aorta, endocardium and cardinal vein. From E11.5 and onwards, the *Etv2* message becomes extinct ([@b25-molce-38-12-1029]; [@b44-molce-38-12-1029]; [@b52-molce-38-12-1029]; [@b75-molce-38-12-1029]). The importance of ETV2 in embryogenesis was revealed by a series of seminal findings from three independent groups. In 2005, Lin and fellow colleagues ([@b89-molce-38-12-1029]) reported that *etsrp,* the *zebrafish* homologue to mammalian ETV2, is one of the significantly downregulated genes in the *zebrafish cloche* mutant, which displays defects in both vessel and blood cell development ([@b86-molce-38-12-1029]), compared to controls. Subsequently, the same group demonstrated the vasculogenic function of etsrp in zebrafish ([@b88-molce-38-12-1029]). In agreement with its endothelial specific expression, *etsrp* morpholino led to a significant impairment of vessel formation, whereas overexpression of *etsrp* resulted in an enhanced generation of embryonic vasculature. Rescuing the vascular defects in the *cloche* mutants upon overexpression of *etsrp* indicates that etsrp functions downstream of the cloche when generating embryonic vasculatures. In mice, we, for the first time, revealed an indispensable function of ETV2 in the development of vessels and blood cells ([@b52-molce-38-12-1029]). Complete absence of both vascular structures and hematopoietic cells in *Etv2* deficient mice embryos leads to embryonic lethality between E9.5 and E10.5. Mechanistically, ETV2 directly binds promoters or enhancers of genes that are critical for endothelial and hematopoietic cell lineages. Similar findings were reported by two groups as the two generated *Etv2* gene trap mice and *Etv2-gfp* knockin mice, respectively ([@b25-molce-38-12-1029]; [@b44-molce-38-12-1029]). With the addition of the finding that *Xenopus er71* has a potent vasculogenic function ([@b66-molce-38-12-1029]), it is clear that ETV2 is indispensable in vessel and blood cell development.

MOLECULAR MECHANISMS OF ETV2 IN REGULATING CARDIOVASCULAR DEVELOPMENT
=====================================================================

[Figures 1B and 1C](#f1-molce-38-12-1029){ref-type="fig"} summarize the findings regarding the molecular mechanisms of ETV2. The very first clue as to how ETV2 regulates cardiovascular cell lineage development was reported by our group and showed that ETV2 directly binds to the ETS consensus sequence (GGAA/T) ([@b37-molce-38-12-1029]; [@b38-molce-38-12-1029]) in the promoter of the *Flk1* gene, leading to the induction of the gene expression ([@b52-molce-38-12-1029]). In this study, it was also shown that overexpression of ETV2 can generate FLK1^+^ mesoderm as well as endothelial and hematopoietic cells in differentiating ESCs in a serum-free condition. In subsequent studies, *Sox7, Lmo2*, *Tie2*, *Nfac1*, were identified as direct targets of ETV2 ([@b4-molce-38-12-1029]; [@b50-molce-38-12-1029]; [@b53-molce-38-12-1029]; [@b67-molce-38-12-1029]). Rather than performing Chromatin Immunoprecipitation (ChIP) assay on the targeted ones, a recent study ([@b58-molce-38-12-1029]) performed a ChIP-sequencing analysis to reveal the direct downstream target genes of ETV2 at a genome wide analysis level and found that ETV2 can not only bind to promoters or enhancers of already known target genes including *Flk1 and Cdh5* but also other genes that perform critical roles in vascular endothelial and hematopoietic cells. Among these genes are *Scl, Gata2, Meis1, Dll4, Notch1, Nrp1/2, Flt4, Fli1, RhoJ, Mapk*. Thus, these results strongly indicate that ETV2 regulates the endothelial and hematopoietic programs in early stage embryos through direct binding to the ETS elements present in the aforementioned genes ([Fig. 1C](#f1-molce-38-12-1029){ref-type="fig"}).

The ETS factors have been shown to interact with other proteins when regulating target genes ([@b20-molce-38-12-1029]; [@b80-molce-38-12-1029]; [@b99-molce-38-12-1029]). Furthermore, several studies showed that ETV2 can form a transcription complex with other proteins ([Fig. 1C](#f1-molce-38-12-1029){ref-type="fig"}). In 2008, De Val et al. reported that the interaction of ETV2 and FOXC2 (forkhead transcription factor) synergistically induces the expression of endothelial and hematopoietic genes ([@b19-molce-38-12-1029]). Recently, we demonstrated that OVOL2, a zinc finger transcription factor, directly binds to ETV2 to cooperatively generate FLK1^+^ mesoderm and vascular endothelial and hematopoietic cell lineages from mouse ESCs ([@b46-molce-38-12-1029]). Interestingly, stability of ETV2 was significantly enhanced upon the overexpression of OVOL2, suggesting a possible mechanism for the cooperative interaction of the two proteins. Additionally, [@b81-molce-38-12-1029] reported Gata2 as the interacting protein of ETV2. This interaction was cooperative in activating important genes for vascular endothelial and blood cell development. It is of note that all the identified proteins of ETV2 interacting partners have been implicated in embryonic vessel and blood cell development ([@b51-molce-38-12-1029]; [@b59-molce-38-12-1029]; [@b79-molce-38-12-1029]; [@b94-molce-38-12-1029]; [@b95-molce-38-12-1029]; [@b96-molce-38-12-1029]). All in all, it is evident that ETV2 can form a multiprotein transcription complex to control the expression of target genes. Thus, revealing more ETV2 interacting proteins in the regulation of endothelial and hematopoietic genes would be an important next step.

One of the major outstanding questions would be the mechanisms, which regulates the expression of ETV2 ([Fig. 1B](#f1-molce-38-12-1029){ref-type="fig"}). In the first report conducted by our group, treatment of inhibitors of BMP (noggin), NOTCH (DAPT) and WNT (DKK1) led to a significant decrease in the expression of *Etv2* and the generation of FLK1^+^ mesoderm ([@b52-molce-38-12-1029]). The reduced genesis of the FLK1^+^ mesoderm in the presence of the inhibitors was reversed upon the overexpression of *Etv2*, suggesting that ETV2 functions downstream of these signaling pathways. In addition, several studies reported the transcriptional regulation of ETV2. [@b25-molce-38-12-1029] reported that the upstream region of the *Etv2* promoter can be bound by NKX2-5, a key transcription factor for heart development ([@b60-molce-38-12-1029]; [@b93-molce-38-12-1029]), positing NKX2-5 as an direct upstream factor of *Etv2* in the generation of endocardium in the heart ([@b25-molce-38-12-1029]). However, no defects were observed in endothelial cell development in *Nkx2-5* deficient mouse embryos and the failure of increasing endothelial genes upon overexpression of *Nkx2-5* in differentiating mouse ESCs ([@b10-molce-38-12-1029]; [@b60-molce-38-12-1029]; [@b93-molce-38-12-1029]). Indeed, overexpression of *nkx2-5* in *zebrafish* significantly decreases the expression of *etsrp* with concomitant upregulation of cardiac genes ([@b83-molce-38-12-1029]), suggesting that endothelial expression of ETV2 is NKX2-5 independent. In addition to the role of FOXC2 as an ETV2 interacting protein, it was reported that Fox proteins could function upstream of *etsrp* when generating endothelial and hematopoietic cells in *zebrafish* ([@b97-molce-38-12-1029]). In this study, the authors found enhancers that drove the endothelial expression of *etsrp*. While one of the enhancers of *etsrp* was occupied by foxc1a/fox1b, the expression of *etsrp* was significantly reduced by *foxc1a/fox1b* morpholino. Given the finding that FOXC2 can interact with ETV2 to modulate the expression of vascular endothelial and hematopoietic genes ([@b19-molce-38-12-1029]), these results suggest the critical function of FOXC protein in ETV2-mediated cardiovascular development. Through the use of the mouse ESC differentiation system and mouse genetics, it was shown that Mesoderm posterior 1 (MESP1) and CREB (CRE binding protein) play important roles in *Etv2* transactivation ([@b82-molce-38-12-1029]; [@b107-molce-38-12-1029]). *Etv2* expression can be activated by cAMP/PKA/CREB signaling in differentiating mouse ESCs ([@b107-molce-38-12-1029]). In this study, the authors showed that CREB can directly bind to the CRE binding elements in *Etv2* upstream regions. Blocking ETV2 expression using siRNA leads to the reduction of PKA/CREB-mediated induction of endothelial and hematopoietic cell lineages. In accordance to this, a recent study reported ([@b82-molce-38-12-1029]) that Mesp1 can activate the expression of *Etv2* through binding to the CRE element. This transactivation appears to be CREB-dependent as shown by the abrogated *Etv2* promoter activity upon co-transfection of MESP1 and dominant negative form of CREB. Interestingly, the study found that the majority of ETV2^+^ cells originate from MESP1^+^ cells and that the deficiency of *Etv2* in MESP1^+^ cells causes embryonic lethality that leads to defects in vascular and blood cell generation, which is reminiscent of *Etv2* knockout mice. This supports the linear correlation between MESP1 and ETV2 in vascular endothelial and hematopoietic cell development. However, given that the overexpression of *Mesp1* can promote the generation of cardiac lineage cells with suppression of hematopoiesis ([@b8-molce-38-12-1029]; [@b55-molce-38-12-1029]), this appears contradictory to the results. Nonetheless, these studies clearly indicate that the transcription factors involved in early mesoderm development as well as cardiovascular generation and maturation play an important role in the regulation of ETV2 expression. Not only mapping sequential order of the transcription factors and identifying additional factors required for ETV2 expression, but it would also be interesting to study how these transcription factors cross talk with the aforesaid signaling pathways in governing ETV2 expression.

INTERPLAY BETWEEN ETV2 AND OTHER ETS FACTORS IN ESTABLISHING CARDIOVASCULAR SYSTEM
==================================================================================

As discussed, there are more than 20 ETS factors found in mammals and some of them play significant roles in vascular system development and function ([@b26-molce-38-12-1029]; [@b61-molce-38-12-1029]; [@b74-molce-38-12-1029]). Having confirmed the transient but potent vasculogenic activity of ETV2 in early mouse embryos (i.e. its expression is not detectable beyond E11.5) ([@b25-molce-38-12-1029]; [@b44-molce-38-12-1029]; [@b52-molce-38-12-1029]), many have been puzzled by how the vasculatures develop and are maintained throughout embryogenesis. In this regard, two groups have demonstrated a positive feedback loop mechanism between ETV2 and other ETS factors, at least Fli1 ([@b1-molce-38-12-1029]; [@b58-molce-38-12-1029]). In 2014, [@b1-molce-38-12-1029], showed using *Fli1* knockout mice that while *Fli1* messages were significantly decreased in *Etv2* knockout mouse embryos, other ETS factors such as *Ets1/2, Elf1/2* and *Etv6* showed comparable levels of expression. The expression of *Fli1* is directly upregulated by ETV2 as well as by FLI1 itself through the ETS binding sites on the *Fli1* promoter as demonstrated by the ChIP-PCR and luciferase-based promoter assays. Interestingly, that fact that FLI1 binds to its own promoter was observed at E11.5, which is the time in which the ETV2 expression becomes extinct, but not at E9.5, which is when the ETV2 message is still abundant. Also, the ChIP-PCR analysis revealed *in vivo* occupancy of FLI1 on the promoters of *Tie2* and *Cdh5* at E11.5, but not at E9.5 embryos. Consistently, several key endothelial genes, such as *Tie2* and *Cdh5,* induced by ETV2 showed reduced levels of expression in *Fli1* deficient embryos as well as *Fli1* knockdown primary endothelial cells. These results suggest that the function of FLI1 replaces the function of ETV2 at least partly for endothelial cell survival and vascular maintenance at the midgestation stage. Subsequently, [@b58-molce-38-12-1029] reported a similar feedback regulation mechanism between ETV2 and FLI1. Performing genome wide analysis with ChIP-sequencing comprehensively revealed direct targets of ETV2, which can be classified into VEGF signaling/endothelial lineage specification genes, NOTCH/MAPK signaling and RHO GTPase. The ETS factors such as *Fli1*, *Ets1/2, Erg* and notably *Etv2* itself were identified as potential targets of ETV2 in differentiating mESCs. In agreement with the results, overexpression of *Etv2* led to the immediate induction of *Fli1*, suggesting that *Fli1* is a direct downstream target of ETV2. Indeed, the ChIP-PCR experiment showed *in vivo* occupancy of ETV2 on *Fli1* genomic DNA. The findings that *Fli1* null embryos and mouse ESCs showed comparable levels of expression of *Etv2* compared to wild type controls but overexpression of *Fli1* in mouse ESCs did not induce *Etv2* message further support the argument ([@b58-molce-38-12-1029]). Similar to the findings discussed above ([@b1-molce-38-12-1029]), key endothelial and hematopoietic genes such as *Tie2*, *Cdh5, Lmo2* and *Scl*, which are the direct targets of ETV2, can also be directly regulated by *Fli1* when ETV2 expression is not detected in differentiating ESCs. Given that ETV2 can activate its own promoter, these results suggest the following model; ETV2 triggers a genetic program for endothelial and hematopoietic lineage development through its transcriptional activation function (i.e. positive autoregulation and transactivation of target genes). Once the endothelial cells and hematopoietic cells are generated when the ETV2 expression is silent, other ETS factors, especially FLI1 induced by ETV2 ensure further establishment and maintenance of the vessel and blood systems. Thus, molecular and biochemical studies that uncover the functional significance of other ETS factors in the context of FLI1 in generating vessel and blood cells would be worthy areas to pursue.

CARDIOVASCULAR CELL FATE DETERMINING ROLE OF ETV2
=================================================

The first emerging FLK1^+^ mesoderm in developing mouse embryos have the potential to differentiate into vascular endothelial, hematopoietic, muscle cell lineages including cardiomyocyte and smooth muscle cells ([@b13-molce-38-12-1029]; [@b22-molce-38-12-1029]; [@b23-molce-38-12-1029]; [@b24-molce-38-12-1029]; [@b64-molce-38-12-1029]; [@b108-molce-38-12-1029]), suggesting that FLK1^+^ mesoderm functions as a multipotent progenitor in cardiovascular cell lineages. A series of studies showed that FLK1^+^ mesoderm can be subdivided into two distinct cell populations; FLK1^+^PDGFRα^+^ (platelet-derived growth factor receptor α) with cardiogenic potential and FLK1^+^PDGFRα^−^ cells with endothelial and hematopoietic potential ([@b36-molce-38-12-1029]; [@b56-molce-38-12-1029]; [@b76-molce-38-12-1029]). However, mechanisms that determine the cell fate of FLK1^+^ mesoderm into the cell population remain to be elucidated. Given the role of transcription factors in determining cell identity ([@b28-molce-38-12-1029]; [@b34-molce-38-12-1029]; [@b41-molce-38-12-1029]; [@b70-molce-38-12-1029]; [@b105-molce-38-12-1029]), it is plausible that ETV2 regulates the multipotency of the FLK1^+^ mesoderm. Indeed, the lack of *Etv2* in mice and mouse ESCs leads to the failure to generate FLK1^+^PDGFRα^−^ cells (we refer this hemoangiogenic FLK1^+^ cells) with concomitant augmentation of FLK1^+^PDGFRα^+^ cells (we refer this cardiogenic FLK1^+^ cells) ([@b56-molce-38-12-1029]; [@b58-molce-38-12-1029]). Also, reduced expression of genes of vascular endothelial and blood cells and augmentation of cardiac genes were observed in *Etv2* knockout embryos ([@b52-molce-38-12-1029]). Inversely, the overexpression of *Etv2* in differentiating mouse ESCs leads to a significant increment of hemoangiogenic FLK1^+^ cells at the expense of cardiogenic FLK1^+^ cells. The capability of ETV2 to induce hemoangiogenic potential is further strengthened when GATA2 and SCL are co-expressed ([@b57-molce-38-12-1029]). Additional supporting results in this field have been reported from studies in *zebrafish*. In 2007, Schoenebeck et al. (2017), showed that the overexpression of *etsrp* together with *scl* leads to the expansion of hematopoietic and endothelial cell area with a reduction in the cardiac field as well as heart size. The observed phenotype was reversed upon injection of *etsrp* and *scl* morpholino in *zebrafish* embryos. A similar finding was reported by the knockdown of *etsrp* alone in *zebrafish* embryos ([@b67-molce-38-12-1029]). In this study, the authors further showed using etsrp-gfp cells that etsrp^+^ cells are deficient in *etsrp* fated to cardiogenic cell lineages. These results suggest that ETV2 functions as an essential cell fate determinant between hemoangiogenic and cardiogenic mesoderms. Likewise, transcriptional regulation of such antagonistic relationships between hemoangiogenic and cardiogenic cell lineage specification is evident in other studies as well. Injection of *nkx2-5* into zebrafish embryos reduced the expression of endothelial and blood cell markers such as *etsrp, scl* and *pu.1,* but significantly expanded the hand2^+^ cardiac boundary ([@b83-molce-38-12-1029]). When *Mesp1*, another key cardiogenic transcription factor in differentiating mESCs, *was* overexpressed, the antagonistic developmental outcomes have also been reported ([@b8-molce-38-12-1029]; [@b55-molce-38-12-1029]).

Further insight as to how ETV2 regulates the cell fate of FLK1^+^ mesoderm was suggested by [@b56-molce-38-12-1029] as the study reported the first evidence of the role of ETV2 and WNT-β-catenin signaling in this process. The authors found reduced expression of genes involved in WNT-β-CATENINE signaling with decreased cardiomyocyte generation when *Etv2* was overexpressed in differentiating ESCs. In sharp contrast, over-expressing *β-catenin* reversed the ETV2-induced hemoangiogenic cell lineage generation. However, the proposed mechanism was not consonant with the knockout mice study in which deficiency of *β-catenin* in FLK1^+^ mesoderm resulted in no obvious phenotypic defects in heart formation ([@b87-molce-38-12-1029]). Therefore, further investigation to explain the molecular mechanism of ETV2 in determining the cell fate of FLK1^+^ mesoderm is required.

DIRECT CELL REPROGRAMMING AND ETV2
==================================

The monumental findings from the studies conducted by [@b30-molce-38-12-1029], [@b104-molce-38-12-1029] and recently the Yamanaka group ([@b90-molce-38-12-1029]; [@b91-molce-38-12-1029]) have challenged the longstanding consensus that the differentiation process is unidirectional and produces a progressive loss of differentiation potential like a ball rolling from the top of a mountain to the ground and thus generates cells with an irreversibly determined fate ([@b101-molce-38-12-1029]). Fueled by the Yamanaka's finding that four pluripotency factors (OCT4, SOX2, KLF4, and C-MYC) can generate embryonic stem like cells, such as induced pluripotent cells (iPSCs) from differentiated somatic cells ([@b90-molce-38-12-1029]; [@b91-molce-38-12-1029]), considerable efforts have been focused on regenerative medicine, which aims to develop the generation of functional cells or even tissues for autologous cell replacement therapies. However, the clinical applicability of the iPSC-based approaches have been significantly limited due to the inefficient generation of targeted cells and tumorigenic potential ([@b15-molce-38-12-1029]; [@b48-molce-38-12-1029]), necessitating a novel means to overcome these obstacles. In agreement with the previous studies ([@b43-molce-38-12-1029]; [@b45-molce-38-12-1029]; [@b104-molce-38-12-1029]; [@b106-molce-38-12-1029]), the overexpression of cell type or tissue specific transcription factors is sufficient to directly convert or reprogram somatic cells into targeted cells such as cardiomyocytes, neuron or hepatocytes that bypass the iPSC stages *in vivo* ([@b39-molce-38-12-1029]; [@b40-molce-38-12-1029]; [@b69-molce-38-12-1029]; [@b78-molce-38-12-1029]; [@b84-molce-38-12-1029]; [@b100-molce-38-12-1029]).

Considering that cardiovascular diseases (CVDs) are the most serious diseases in both the United States and the world ([@b65-molce-38-12-1029]), a great number of researchers have been investigating an efficient way to generate autologous functional endothelial cells for cell therapy. Over the past 15 years, interrogating potential of PSCs (i.e., embryonic stem cells and induced pluripotent stem cells) and endothelial progenitor cells that can generate endothelial cells for therapeutic purposes has been an active research area. As discussed, the recent emergence of the direct reprogramming technology has also prompted investigators to seek novel methods to generate functional endothelial cells directly from somatic cells, which can be applied to the treatment of CVD patients. In 2012, Ginsberg et al. showed that ETV2 together with other ETS factors such as FLI1 and ERG can convert human mid gestation c-kit^−^ lineage-committed amniotic cells (ACs) into endothelial cells ([@b29-molce-38-12-1029]). Interestingly, in analogy to embryonic vessel development, the function of ETV2 was only required in the beginning phase of the reprogramming process and the onward steps were completed by FLI1 and ERG in conjunction with the suppression of TGF-β signaling. The reprogrammed endothelial cells were able to evidence neovascularization *in vivo*. However, the combination of factors was only applied to the ACs, and not to adult somatic cells. In a subsequent study by [@b32-molce-38-12-1029], it was shown that the mixture of transcription factors crucial for vessel development (FOXO1, ETV2, KLF2, TAL1, and LMO2) was able to directly reprogram mouse adult skin fibroblast into endothelial cells. In contrast, we and another group reported direct cell reprogramming of human dermal fibroblasts into endothelial cells by overexpressing ETV2 alone ([@b54-molce-38-12-1029]; [@b63-molce-38-12-1029]). Similarly, skeletal muscles can be converted into endothelial cells in zebrafish. Collectively, these results suggest a potent determinant function of ETV2 in converting non-endothelial cells into endothelial cells and that ETV2 might function as a therapeutic agent for treating CVDs. However, the use of lentiviral or retroviral delivery systems in these studies, which can alter the genomic integrity, is not compatible with clinical use. Therefore, to design novel tools with non-integrating materials such as modified mRNA, small molecules or chemicals is an imperative need in the field of direct reprogramming. Additional efforts should be made to generate specific types of endothelial cells such as arterial, venous and lymphatic ECs.

CONCLUSION
==========

By virtue of extensive studies over the past few years, we have a better understanding on the critical function of ETV2 in the genesis of the vessel, blood and heart in developing mouse embryos. As discussed, one of the salient observations in ETV2 biology is its transient expression in vessel and blood cells ([@b25-molce-38-12-1029]; [@b44-molce-38-12-1029]; [@b52-molce-38-12-1029]). The intricate interplay between ETV2 and FLI1 is proposed as a means to maintain functional vessels and hematopoietic cells throughout embryogenesis and perhaps in adults ([@b1-molce-38-12-1029]; [@b58-molce-38-12-1029]). However, the mechanisms, in which the ETV2 expression is off, remain to be determined. The switch-off of the proposed upstream signals as previously discussed could be one possible explanation. Additional means of regulation would be active ways to restrict the expression of ETV2 in a certain narrow window of time to ensure proper development of vessel and hematopoietic cells. Indeed, *let7-a* miRNA is capable of targeting *zebrafish etsrp*, resulting in the reduction of expression of both vascular endothelial and hematopoietic markers ([@b62-molce-38-12-1029]). Given the recent report that *Kdm1a*, histone demethylase, in *zebrafish* promotes hematopoietic cell development by suppressing *etsrp* function ([@b92-molce-38-12-1029]), epigenetic modifications of the ETV2 genomic loci would be another possible mechanism. In addition, it was reported that the sustained expression of ETV2 in endothelial and hematopoietic cells caused abnormal development and endothelialization, respectively ([@b35-molce-38-12-1029]). Thus, future studies on the safe-guard mechanisms of the ETV2 expression are warranted.

We and others unequivocally proved the potent vasculogenic function of ETV2 in developing mouse embryogenesis. As previously stated, the message becomes extinct once the vessel and hematopoietic cells develop. This raised a question as to the functional significance of ETV2 in post-natal life. In this regard, [@b53-molce-38-12-1029] found the enriched expression of ETV2 in BM HSCs and reported that *Mx1-cre* driven deletion of *Etv2* led to the decrease in the number and repopulating capacity of BM HSCs. The authors claimed the increased death of BM HSC in the absence of *Etv2* as an etiology of the observed phenotypes. Mechanistically, they showed that ETV2 can directly regulate *Tie2* expression, but failed to link how the reduced *Tie2* expression is related to the death of BM HSCs. Recently, we have found that the endothelial ETV2 acts as a critical regulator in neovascularization in response to injury ([@b71-molce-38-12-1029]). The *Etv2* expression in endothelial cells is reactivated after injury. Mice deficient in *Etv2* in endothelial cells exhibited a significant impairment of new vessel formation upon injury such as wounding, eye injury and hindlimb ischemia. Interestingly, single delivery of lentiviral *Etv2* not only promotes the recovery of blood perfusion, but also augments proliferation of endothelial cells as well as smooth muscle cells, leading to neovascularization and tissue repair in the injured hindlimbs. These results suggest that ETV2 in adults plays an important role in vessel and blood construction systems under physiological conditions. Extending from these findings ([@b71-molce-38-12-1029]), investigation of the function of ETV2 in pathological settings such as tumor angiogenesis and diabetics related vessel defects would be of significant interest from a therapeutic stand point. Last, but not least, ETV2 alone or together with other endothelial transcription factors were reported to directly convert nonendothelial cells into endothelial cells ([@b29-molce-38-12-1029]; [@b32-molce-38-12-1029]; [@b54-molce-38-12-1029]; [@b63-molce-38-12-1029]; [@b98-molce-38-12-1029]). As reviewed above, the identity of the converted endothelial cells is not clear: are they venous, arterial or lymphatic endothelial cells, functionally and (epi) genetically? What are the mechanism of the direct reprogramming by ETV2? Based upon our results as previously discussed, can ETV2 in clinically compatible forms be developed with high efficiency for clinical use *in vivo*?

In summary, ETV2 is an indispensable transcription factor and plays a crucial role in vessel development and function. Recent findings have revealed additional capabilities of ETV2 in cell reprogramming. Thus, deciphering the mechanisms by which ETV2 is regulated in governing these processes would provide a novel research venue for the basic and translational aspects of endothelial cell biology.
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![Regulation of the expression and function of ETV2. (A) A schematic structural diagram of the complex of the ETS domain of PU.1 in gold and DNA in purple (deposited on The RCSB PDB [www.rcsb.org](www.rcsb.org); DOI: 10.2210/pdb1pue/pdb) ([@b5-molce-38-12-1029]; [@b49-molce-38-12-1029]). (B) In early embryos or differentiating mouse ES cells, BMP/NOTCH/WNT pathways act upstream of ETV2 expression. During this process, transcriptional activation of *Etv2* is induced by at least MESP1, CREB and FOXC2. let7a functions to inhibit ETV2 protein synthesis. It is of note that the relationship between BMP/NOTCH/WNT pathways to MESP, CREB and FOXC2 is not known. Also, whether the three transcription factors interact each other in regulating *Etv2* gene expression remain elucidated. (C) ETV2 can bind and activate promoters/enhancers of genes critical for endothelial and hematopoietic cell development. OVOL2, FOXC2, GATA2 are reported to interact with ETV2 in mediating these regulation. Whether the three transcription factors can form a transcriptionally active complex remains determined.](molce-38-12-1029f1){#f1-molce-38-12-1029}
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